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The hepatitis B virus (HBV) X protein (pX) is implicated in hepatocarcinogenesis by an unknown mechanism. pX variants encoded by HBV genomes found integrated in genomic DNA from liver tumors of patients
with hepatocellular carcinoma (HCC) generally lack amino acids 134 to 154. Since deregulation of mitogenic
pathways is linked to oncogenic transformation, herein we define the pX region required for mitogenic pathway
activation. A series of pX deletions was used to construct tetracycline-regulated pX-expressing cell lines. The
activation of the mitogenic pathways by these pX deletions expressed in the constructed cell lines was measured
by transient transreporter assays, effects on endogenous cyclin A expression, and apoptosis. Conditional
expression of pX51-140 in AML12 clone 4 cell line activates the mitogenic pathways, induces endogenous cyclin
A expression, and sensitizes cells to apoptosis, similar to wild-type (WT) pX. By contrast, pX1-115 is inactive,
supporting the idea that amino acids 116 to 140 are required for mitogenic pathway activation. Moreover, this
pX deletion analysis demonstrates that WT pX function is modulated by two regions spanning amino acids 1
to 78 and 141 to 154. The N-terminal X1-78, expressed via a retroviral vector in WT pX-expressing 4pX-1 cells,
coimmunoprecipitates with WT pX, indicating this pX region participates in protein-protein interactions
leading to pX oligomerization. Interestingly, pX1-78 interferes with WT pX in mediating mitogenic pathway
activation, endogenous gene expression, and apoptosis. The C-terminal pX region spanning amino acids 141
to 154 decreases pX stability, determined by pulse-chase studies of WT pX and pX1-140, suggesting that
increased stability of naturally occurring pX variants lacking amino acids 134 to 154 may play a role in HCC
development.

Epidemiologic evidence (6) links chronic hepatitis B virus
(HBV) infection in humans to development of hepatocellular carcinoma (HCC). Comparative studies of mammalian
and avian hepadnaviruses, transgenic animal studies, and
cell culture transformation studies (reviewed in references 2
and 16) implicate the 16.5-kDa X protein (pX) of HBV in
HCC development. Although the mechanism by which pX
mediates hepatocellular carcinogenesis is not yet understood, it is known that pX is a multifunctional regulatory
protein required for viral infection (17, 48). Well-established functions of pX include activation of cellular Src by
calcium signaling (12–15, 25), resulting in pX-dependent
activation of the mitogenic Ras–Raf–mitogen-activated protein kinase (MAPK), Jun N-terminal protein kinase (JNK),
and p38 MAPK pathways (7–9, 41, 42).
Another well-established function of pX is its effect on transcription (2, 14). pX increases transcription of select viral (20)
and diverse cellular genes mediated by cis-acting elements,
including AP1 (9, 22, 32), AP2 (38), cis-acting replication element (CRE) (4, 5, 45), and NF-B (30, 39) sites. Since pX is
not a sequence-specific DNA binding protein, the broad effects
of pX on transcription are linked to its ability to activate the
mitogenic pathways. Specifically, the consequence of the pX* Corresponding author. Mailing address: Department of Basic
Medical Sciences, Purdue University, 625 Harrison Street, West Lafayette, IN 47907-2026. Phone: (765) 494-8131. Fax: (765) 494-0781.
E-mail: andrisao@purdue.edu.
䌤
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dependent activation of the mitogenic pathways (7, 9, 25, 41,
42) is the activation of their downstream effectors, leading to
enhanced pX-dependent transcription. pX-dependent activation of the mitogenic pathways has been linked to increased
cell cycle progression (12, 28), apoptosis (44), and cellular
transformation of differentiated hepatocytes (40) by deregulation of cellular gene expression. Genes transcriptionally induced by pX and linked to deregulated cell growth include the
cyclins (28), tumor necrosis factor alpha/tumor necrosis factor
receptor I, Fas/FasL, and p53-responsive genes (44; W.-H.
Wang and O. M. Andrisani, unpublished results).
In addition to mitogenic pathway activation, pX activates
transcription directly via protein-protein interactions with specific components of the basal transcriptional apparatus (18, 24,
29, 34) and via direct interactions with the bZIP family of
CREB/ATF proteins (4, 5, 45). Interestingly, the CREB/ATF
family of transcription factors is the downstream effector of the
mitogenic pathways, activated by phosphorylation in response
to pX action (1). In addition, CREB/ATF proteins are direct
interaction targets of pX (4, 5, 45). Thus, the mitogenic and
transcription functions of pX integrate at the level of CREB/
ATF protein function. The pX-dependent activation of mitogenic pathways and the direct transcriptional effects of pX
likely contribute to pX-mediated hepatocyte transformation.
Various studies have mapped the regions of pX required for
its transactivation function. Amino acids (aa) 50 to 140 of pX
are required for X-protein-dependent transactivation from the
simian virus 40 early promoter (3, 35), the Rous sarcoma virus
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long terminal repeat (27), CRE-driven CREB/ATF transactivation (4), and interaction with the RPB5 subunit of RNA
polymerase II (18). X50-140 also contains the interaction region
for CREB/ATF proteins located between amino acids 50 to
115 (4), transcription factor IIB (TFIIB) (amino acids 102 to
136) (29), and TFIIH (amino acids 110 to 143) (34). In contrast
to the activating region of pX (aa 51 to 140), the pX region
spanning amino acids 1 to 50 was shown to have a repressive
effect on X-protein-mediated transactivation and was reported
to be involved in protein-protein interactions leading to pX
oligomerization (31).
Regarding the pX region(s) required for mitogenic pathway
activation, it was reported that amino acids 58 to 119 of pX are
sufficient to activate the MAPK pathways, assayed in mouse
liver in vivo (33). Since pX is implicated in HBV-mediated
HCC (2, 16) and deregulation of mitogenic pathways is causally linked to oncogenic transformation, we were intrigued by
the naturally occurring pX deletions found in liver tumors of
patients with HCC (36, 43, 46). These pX variants encoded by
integrated HBV genomes contain C-terminal deletions generally lacking aa 134 to 154 (36, 43, 46), suggesting that these
deletions might alter the potential of pX in activating the
mitogenic pathways. Accordingly, we undertook a systematic
deletion analysis of pX to define the pX region required for
mitogenic pathway activation. We employ the same pX deletion mutants previously analyzed for mediating pX-dependent
CREB/ATF transactivation (4) and constructed tetracycline
(Tet)-regulated pX-expressing cell lines in the less-differentiated AML12 clone 4 (40). Our earlier studies have demonstrated that tetracycline-regulated expression of wild-type
(WT) pX in AML12 clone 4, i.e., the 4pX-1 cell line, induces
sustained activation of the JNK and p38 MAPK pathways and
transient activation of the Ras-Raf-MAPK pathway (42). Importantly, the consequence of the pX-dependent sustained activation of the cellular stress pathways is the sensitization of
4pX-1 cells to apoptosis (44). Herein, we demonstrate that
pX51-140, conditionally expressed in AML12 clone 4 cell line, is
essential for activation of all the mitogenic pathways, and importantly, pX51-140 sensitizes cells to apoptosis, similar to WT
pX. By contrast, pX1-115 is inactive in both mitogenic pathway
activation and apoptosis. Moreover, we demonstrate that the
function of WT pX is modulated by two regions spanning
amino acids 1 to 78 and 141 to 154. The C-terminal region
determines X-protein stability. The N-terminal region is the
site of direct interaction of pX molecules. Interestingly, expression of pX1-78 exerts a dominant-negative effect on WT pX
function in mediating mitogenic pathway activation, endogenous gene expression, and apoptosis in 4pX-1 cells.

MATERIALS AND METHODS
Plasmid construction. WT X1-154 and X-protein deletion mutants X51-154,
X79-154, X51-140, X51-115, X51-90, X1-140, and X1-115 were amplified by PCR using
pT7-X as a template (45) and cloned into the PvuII and NheI sites of pBI-EGFP
vector (BD Biosciences Clontech). pBI-EGFP vector contains a bidirectional
tetracycline-responsive promoter. X (adw) cloning primers include a Kozak
sequence (26) and a six-histidine tag sequence inserted in frame at the 3⬘end of
X. X1-78 was PCR amplified from pT7-X plasmid in frame with the Myc epitope
at the 3⬘ end and cloned in the BglII and EcoRI sites of the retroviral plasmid
vector pMSCV (BD Biosciences Clontech), containing the puromycin resistance
gene. All plasmid constructs were confirmed by sequencing.
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Cell culture. 4pX cell lines derived from mouse AML12 cell line (47) were
propagated in Dulbecco’s modified Eagle medium/F12 (Life Technologies) containing 10% fetal calf serum (HyClone); a mixture of insulin, transferrin, and
selenium (Life Technologies); 1.0 M dexamethasone; and 50 g/ml gentamicin
with or without 5 g/ml tetracycline as described previously (40). The PT67
retrovirus packaging cell line (BD Biosciences Clontech) was propagated in ␣
modification medium supplemented with 100 units/ml penicillin G sodium, 100
g/ml streptomycin, 4 mM L-glutamine, 100 mM sodium pyruvate, 2.4 mg/ml
sodium bicarbonate, and 10% fetal bovine serum.
Establishment of stable 4pX cell lines expressing X-protein deletions. Subconfluent cultures of AML12 clone 4 (40) expressing the tetracycline-controlled
transactivator tTA (23) were cotransfected with 10 g of pBI-EGFP-X deletion
plasmids containing inserts X51-154, X79-154, X51-140, X51-115, X51-90, X1-140, and
X1-115, and 2 g of pCGN plasmid containing the hygromycin resistance gene by
the calcium phosphate coprecipitation method. Stable transformants were selected with 200 units/ml hygromycin in the presence of 5 g/ml tetracycline.
Well-separated colonies were each transferred to a plate and propagated in
medium containing 200 units/ml hygromycin. Positive clones were screened by
real-time PCR monitoring tetracycline-regulated expression of X, performed as
described previously (28).
Transient transfections. Reporter plasmid pFR-luc, CMV-␤-gal, and transactivator plasmids pFA-Elk-1/pFA-c-Jun/pFA-chop were cotransfected into 4pX
cells using the FuGENE 6 method. WT or X-protein deletion mutants were
expressed 24 h after transfection by tetracycline removal. Luciferase activity was
determined 24 h following pX expression using the luciferase assay system
(Promega), normalized per microgram of protein extract or ␤-galactosidase
activity.
Pulse-chase studies. Whole-cell extracts were isolated in radioimmunoprecipitation assay buffer from 4pX-1 and 4pX1-140 cultures expressing pX and pX1-140,
respectively, for 24 h, labeled with [35S]methionine as described previously (40),
and chased for 0 to 4 h as indicated. Immunoprecipitations with X antibody,
kindly provided by B. Slagle, were performed as described previously (40) and
analyzed by 14% sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) and autoradiography.
Establishment of retrovirus-producing cell lines. Plasmids pMSCV, pMSCVEGFP, and pMSCV-X1-78 were transfected into the PT67 cell line. Stable transformants were selected with 2.5 g/ml puromycin. Single colonies were each
transferred to a plate and propagated in medium containing 2.5 g/ml puromycin. Positive clones were screened by Western blot analyses and immunostaining
with Myc antibody recognizing the Myc epitope fused to pX1-78.
Retrovirus production and viral titer determination. Retrovirus-producing
PT67 stable cell lines, PT67-Vector, PT67-EGFP, and PT67-X1-78, were grown
without puromycin to 60 to 80% confluence. Viral supernatants were harvested
in 12-h intervals until the cells were no longer viable. Supernatants were filtered
through 0.45-m cellulose acetate filter and stored at ⫺80°C. Viral titer was
determined using NIH 3T3 cells as described by the manufacturer (BD Biosciences Clontech).
Retrovirus infection. A total of 5 ⫻ 104 to 10 ⫻ 104 AML12 clone 4 or 4pX
cells were infected with 1 ml (2 ⫻ 105 CFU/ml) of viral supernatant for 12 to 24 h
in the presence of 8 g/ml Polybrene. Confluent cells were passaged to 6-cm
dishes, followed by expression of pX for 12 to 24 h as indicated.
In vitro JNK assays. 4pX cells were serum starved as described previously (40)
for 12 h; pX synthesis was initiated by tetracycline removal for 1 to 6 h in medium
containing 10% fetal calf serum. Cells were harvested in chilled hypotonic lysis
buffer (150 mM NaCl, 16 mM Na2HPO4, 4 mM NaH2PO4, 0.1% Triton X-100,
0.1 mM phenylmethylsulfonyl fluoride, 100 M Na3VO4, 20 g/ml leupeptin, 50
mM NaF, 1 mM benzamidine) and sonicated on ice for 10 seconds. Lysates were
clarified by centrifugation, and protein concentration was determined by the
Bio-Rad protein assay. One milligram of cellular extract was incubated with 1 g
of glutathione S-transferase (GST)–c-Jun (1-79) beads (Stratagene) for 1 h at
4°C. The beads were collected by centrifugation for 2 min at 500 ⫻ g, washed
three times with cold phosphate-buffered saline containing Tween 20, and kinase
reaction was performed by adding to the beads 25 l of kinase buffer (50 mM
Tris, pH 7.5, 10 mM MgCl2, 1 mM EGTA, 50 M ATP), 1 l [␥-32P]ATP (6,000
Ci/mmol; NEN); incubation was for 20 min at 30°C. Analysis was carried out by
12% SDS-polyacrylamide gel electrophoresis, and autoradiography. JNK activity
was quantified using the SCION IMAGE software.

RESULTS
To define pX regions required for mitogenic pathway activation, we constructed tetracycline-regulated cell lines express-
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FIG. 1. Diagram of pX deletions cloned in the tetracycline-regulated expression vector pBI-EGFP used for the construction of tetracycline-regulated cell lines.

ing various pX deletions in the AML12 clone 4 cell line that
expresses the tetracycline-controlled transactivator tTA (40).
Importantly, the AML12 clone 4 cell line supports low-level,
tetracycline-regulated pX expression (40, 42, 44), similar to pX
expression levels observed during viral infection (21), rendering this cellular model physiologically relevant. Furthermore,
our earlier studies have linked pX-dependent mitogenic pathway activation to specific cell growth outcomes, i.e., cell cycle
progression (28) and apoptosis (44).
Our rationale for studying these pX deletions (Fig. 1) is
based on the results of our earlier studies (4), demonstrating
that pX51-140 is required for CRE/CREB-mediated transactivation, whereas pX51-115 is transcriptionally inactive but sufficient for enhanced CREB/ATF CRE binding and CRE-mediated transrepression. Positive clonal cell lines displaying
tetracycline-regulated expression of the X transcript were selected by real-time PCR, employing RNA isolated from putative clones grown in the presence and absence of tetracycline
for 24 h. The real-time PCR assay is based on the fluorescence
emitted by the SYBR green dye upon intercalation to the
synthesized double-stranded cDNA. The fluorescence intensity
corresponding to the cycle threshold value is the CT value (28).
CT values obtained for each clonal cell line expressing the
indicated X deletions are shown in Table 1. Although the CT
values are not identical for all the generated clonal cell lines,
the expression of X is within a similar range and, importantly,
displays tetracycline-regulated expression.
Transient transreporter assays in 4pX clonal cell lines. The
transreporter assay is comprised of two plasmids transiently
cotransfected in a cell line of interest to assess activation of a
specific signaling pathway. These include the pFR-luc reporter
containing a synthetic promoter with five tandem repeats of
the yeast GAL4 binding site regulating luciferase gene expression and the pFA-Elk-1, pFA-c-Jun, and pFA-Chop transactivators, expressing the activation domain of Elk1, c-Jun, or
CHOP-10, respectively, in fusion with the yeast GAL4 DNA
binding domain. Activation of the endogenous Ras-RafMAPK, JNK, and p38 MAPK signaling pathways results in the
phosphorylation and activation of the transcriptional activation
domain of ELK-1, c-Jun, and CHOP-10, respectively, resulting
in luciferase expression.
To assess the activation of the Ras-Raf-MAPK pathway, the
pFR-luc reporter and pFA-Elk-1 transactivator were transiently cotransfected in 4pX-1 cells expressing WT pX and in
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each of the 4pX clonal cell lines expressing the various pX
deletions (Fig. 2A). The pX-dependent induction in luciferase
expression in each cell line is the ratio of luciferase expression
in the presence of pX (in the absence of Tet), WT or pX
deletion mutants, versus in the absence of pX expression (in
the presence of Tet). In comparison to WT pX, deletion of the
50 or 78 N-terminal amino acids of pX increased luciferase
induction (in the absence of Tet/in the presence of Tet) in cell
line 4pX51-154 or 4pX79-154, respectively. Likewise, deletion of
the C-terminal 14 amino acids, as in pX deletions expressed in
4pX51-140 and 4pX1-140 cell lines, results in increased pX-dependent luciferase induction (in the absence of Tet/in the
presence of Tet). Importantly, the double deletion mutant
pX51-140 exhibits at least 50% increased luciferase induction
relative to WT pX. By contrast, a larger deletion of the Cterminal region spanning amino acids 116 to 154, as in pX1-115,
results in substantial reduction in mitogenic pathway activation, similar to pX51-90. Intriguingly, in comparison to the inactive pX1-115, expression of pX51-115 activates the transient
transreporter to WT pX levels. Qualitatively, similar results
were obtained with transreporter assays monitoring activation
of the p38 MAPK (Fig. 2B) and JNK pathways (Fig. 2C).
To confirm that the induction (in the absence of Tet/in the
presence of Tet) of luciferase activity observed in the 4pX cell
lines (Fig. 2A to C) is mediated by the X-mediated activation
of the mitogenic Ras-Raf-MAPK, JNK, and p38 MAPK pathways, the respective transreporter assays were performed in
the presence of specific inhibitors for these pathways, namely,
the MEK-1 inhibitor PD 98059 and the JNK- and p38 MAPKspecific inhibitors SP 600125 and SB 202190, respectively (Fig.
2D). Since pX51-140 displays robust activation of all the mitogenic pathways (Fig. 2A to C), we examined the effects of these
inhibitors employing the 4pX51-140 cell line. Increased concentration of these inhibitors resulted in nearly 70% inhibition in
pX51-140-mediated luciferase induction (Fig. 2D). These results
demonstrate that the region of pX spanning amino acids 51140 mediates the activation of the mitogenic pathways.
Induction of endogenous cyclin A expression in 4pX clonal
cell lines. Our earlier studies (28) have demonstrated that in
the 4pX-1 cell line, WT pX induces expression of the endogenous cyclin A gene, reaching maximal (2.5-fold) induction at
12 h after pX expression. The consequence of this transcriptional induction of cyclin A, along with the pX-dependent
induction of the other cyclins, is progression of 4pX-1 cells in

TABLE 1. Screening of pX-expressing 4pX cell lines
CI valuea

Cell line

4pX1-154
4pX51-154
4pX79-154
4pX51-140
4pX51-115
4pX51-90
4pX1-140
4pX1-115

With Tet

Without Tet

26.4
26.0
25.5
23.3
26.4
20.7
24.3
25.0

21.2
20.2
21.2
19.8
21.7
16.4
21.9
23.4

a
CT values of real-time PCR analyses monitoring the expression of pX deletion mutants in the clone 4 cell lines, grown for 24 hours, in the presence or
absence of 5 g/ml tetracycline.
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FIG. 2. Transient transreporter assays performed in the tetracycline-regulated 4pX cell lines expressing WT pX (X1-154) and X deletion mutants
X51-154, X79-154, X51-140, X1-140, X51-115, X1-115, and X51-90. Reporter plasmid pFR-luc (100 ng), CMV-␤-gal (100 ng) and transactivator plasmids
pFA-Elk-1 (100 ng) (A), pFA-Chop-10 (25 ng) (B), and pFA-c-Jun (50 ng) (C) were cotransfected into 4pX cells using the FuGENE 6 method.
(D) Transient transreporter assays in 4pX51-140 cell line employing pFR-luc (100 ng) reporter plasmid and transactivator plasmids pFA-Elk-1 (100
ng), pFA-c-Jun (50 ng), and pFA-Chop-10 (25 ng), indicated as Elk-1, c-Jun, and Chop-10, respectively, as a function of the indicated concentration
of PD 98059, SP 600125, and SB 2021190. WT or X deletion mutants were expressed 24 h after transfection by tetracycline removal. Luciferase
activity was determined 24 h following pX expression using the luciferase assay system (Promega), normalized per microgram of protein extract
or ␤-galactosidase activity. Results are from at least three independent assays, each performed in identical triplicate experiments. Values for the
pX deletion that were statistically significantly different from the value for pX1-154 are indicated by an asterisk(s). pX-dependent induction of the
Ras-Raf-MAPK pathway in the absence of Tet/in the presence of Tet (⫺Tet/⫹Tet) is shown.

the cell cycle (28). Moreover, the pX-dependent cyclin A transcription in 4pX-1 cells is dependent on the sustained, pXdependent activation of the JNK pathway (42). On the basis of
these observations, we employed the 4pX cell lines expressing
the indicated pX deletions to assess their potential in inducing
endogenous cyclin A gene transcription.
Employing real-time PCR, we quantified the pX-dependent
cyclin A mRNA levels (in the absence of Tet/in the presence of
Tet) in total RNA isolated from 4pX cell lines at 12 h after
expression of the indicated pX deletions (Fig. 3A). In comparison to WT pX, only pX1-140 and pX51-140 demonstrate endogenous cyclin A induction. Interestingly, deletions pX51-154,
pX79-154 and pX51-115, despite demonstrating activation of all
the mitogenic pathways (Fig. 2), lack the ability to induce

transcription of endogenous cyclin A gene. On the other hand,
deletions pX1-115 and pX51-90 activate neither the mitogenic
pathways (Fig. 2) nor induce transcription of the endogenous
cyclin A gene (Fig. 3A).
Since sustained, pX-mediated activation of the JNK pathway
is required for cyclin A transcription in the 4pX-1 cell line (42),
we investigated the duration of pX-dependent activation of the
JNK enzyme in each of the 4pX cell lines expressing the indicated deletions. In vitro JNK enzyme assays were performed,
employing cellular extracts isolated in a time course experiment, 1, 2, and 6 h after expression of pX deletions, with
GST–c-Jun as the substrate (Fig. 3B).
Deletions pX1-140 and pX51-140, which induce expression of
the endogenous cyclin A gene (Fig. 3A), exhibit sustained JNK
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FIG. 3. (A) pX-dependent transcriptional induction (in the absence of Tet/in the presence of Tet [⫺Tet/⫹Tet]) of endogenous cyclin
A in the indicated 4pX-expressing cell lines. Total RNA was isolated
12 h following expression of WT pX (X1-154) and X deletion mutants
X51-154, X79-154, X51-140, X1-140, X51-115, X1-115, and X51-90 by tetracycline
removal from serum-starved (18-h) 4pX cell lines. Quantification of
cyclin A mRNA was by real-time PCR performed in identical triplicate
experiments, as described previously (28), using endogenous glyceraldehyde-3-phosphate dehydrogenase as an internal control. Data are
from three independent RNA preparations. P values of the ⫺Tet/
⫹Tet cyclin A induction are as follows: P ⬍ 0.05 for pX1-154, P ⬍ 0.01
for X51-140, and P ⬍ 0.01 for X1-140. (B) In vitro JNK kinase assays
employing cellular extracts isolated from the indicated 4pX cell lines in
a time course experiment 1, 2, and 6 h after tetracycline removal using
GST–c-Jun as the substrate. Sorbitol treatment (15 min, 500 mM) is
used as a positive control. Total JNK enzyme in each sample was
determined by Western blot assay using the JNK antibody. A representative assay from the independent experiments is shown. Quantification was performed by the SCION IMAGE software.

enzyme activation, lasting at least 6 h (Fig. 3B). By contrast,
the duration of JNK activation by pX51-154 and pX1-115 is not
sustained, lasting 2 h or less; furthermore, pX51-90 is incapable
of activating the JNK enzyme (Fig. 3B). Importantly, pX51-154
and pX1-115, which mediate only transient JNK activation (Fig.
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3B), lack the ability to induce endogenous cyclin A transcription (Fig. 3A), in agreement with our earlier observations (42)
and those of others (11). Therefore, only deletions pX1-140 and
pX51-140, which mediate sustained JNK pathway activation
(Fig. 3B), induce endogenous cyclin A transcription (Fig. 3A).
Effects of pX deletions in mediating apoptosis. Expression of
WT pX sensitizes cells to apoptosis (19, 39, 44). In the 4pX-1
cell line, pX sensitizes cells to apoptosis by activating in a
sustained manner the p38 MAPK and JNK pathways (44).
Accordingly, we examined the potential of each of the pX
deletions to mediate apoptosis in the respective 4pX cell line,
employing the same conditions as those used for pX-dependent apoptosis in the 4pX-1 cell line (44). Specifically, 4pX
cultures were grown to confluence, followed by expression of
pX deletions for 24 h; apoptosis was initiated by growth factor
withdrawal, by incubating 4pX cultures in 2% fetal calf serum.
4pX-1 cells grown under these apoptotic conditions undergo
apoptosis at 24 h via the combined pX-dependent activation of
the p38 MAPK and JNK pathways (44). Accordingly, pXdependent apoptosis in 4pX cell lines expressing the indicated
deletions was monitored at 24 h, employing immunofluorescence microscopy detecting active, cleaved caspase 3 (Fig. 4A).
Quantification of these apoptosis assays (Fig. 4B) demonstrates that only deletions pX51-140 and pX1-140, which exhibit
sustained JNK activation (Fig. 3B) and induction of endogenous transcription (Fig. 3A), sensitize cells to apoptosis as the
WT pX does. Importantly, inhibition of the p38 MAPK and
JNK pathways by their specific inhibitors rescues pX51-140mediated apoptosis (Fig. 4B), directly demonstrating that this
apoptosis is a consequence of the activation of the stress pathways by pX51-140, in agreement with our earlier studies (44). By
contrast, the level of apoptosis observed with deletions pX51-154
and pX1-115, which only transiently activate JNK (Fig. 3B), is
similar to that obtained following inhibition of the p38 MAPK
or JNK pathway (Fig. 4B).
Thus, our analyses of the activity of the pX deletion mutants
(Fig. 1), employing transient transreporter assays (Fig. 2), endogenous cyclin A gene expression (Fig. 3A), and apoptosis
(Fig. 4), identify pX51-140 as essential in activating the cellular
mitogenic pathways as well as in mediating the known mitogenic effects on cellular gene expression and the ensuing consequences on cell growth. Likewise, our analyses demonstrate
that pX1-115 only transiently activates the mitogenic pathways
(Fig. 3C), exerting no effect on endogenous gene expression
(Fig. 3A) or apoptosis (Fig. 4).
WT pX contains C- and N-terminal modulatory regions. In
comparison to WT pX, deletion mutant X51-140 consistently
demonstrates increased activity linked to mitogenic pathway
activation (Fig. 2 to 4), suggesting that both the N-terminal and
C-terminal regions of WT pX modulate its potential to activate
the mitogenic pathways.
To understand the role of the C-terminal region spanning aa
141 to 154, we compared the stability of WT pX and pX1-140,
employing pulse-chase studies by in vivo labeling with [35S]methionine (Fig. 5). WT pX is not detectable at 30 min following
labeling with [35S]methionine (Fig. 5), in agreement with similar observations by others (10). In comparison to WT pX,
pX1-140 is readily detected at 30 min following labeling with
[35S]methionine, reaching basal levels by 2 h (Fig. 5). On the
basis of these results, we conclude that the C-terminal region

VOL. 80, 2006

HBV pX51-140 MEDIATES MITOGENIC PATHWAY ACTIVATION

10559

FIG. 4. pX-dependent apoptosis (in the presence and absence of
Tet) in the indicated 4pX cell lines expressing WT pX (X1-154) and X
deletion mutants X51-154, X79-154, X51-140, X1-140, X51-115, X1-115, and
X51-90. Apoptotic growth conditions were as described previously (44).
(A) Apoptosis assayed at 24 h following growth factor withdrawal by
immunofluorescence microscopy employing antibody specific for active, cleaved caspase 3 (Cell Signaling Technology). Hoechst (blue)
stains DNA. (B) Quantification of immunofluorescence images shown
in panel A, employing IMAGE J software. Results are from at least
three independent apoptotic assays, quantifying an average of 5,000
cells per assay.

of pX (aa 141 to 154) determines the stability of the WT pX.
Deletion of this C-terminal region as in pX1-140 results in
increased protein stability.
Regarding the function of the N-terminal region of pX, in
addition to our observations herein, others have demonstrated
that deletion of amino acids 1 to 50 increases pX-mediated
transactivation (31). Moreover, it was reported that this Nterminal region participates in protein-protein interactions
leading to pX oligomerization. To investigate the role of the
N-terminal region of pX, we constructed a nonreplicating ret-

rovirus expressing pX1-78, fused to the Myc epitope at its C
terminus; the pMSCV-X1-78 plasmid was stably integrated in
the pT67 retrovirus packaging cell line (Fig. 6A), resulting in
retrovirus production. Retroviral titers were quantified at approximately 2.5 ⫻ 105 CFU/ml. Infection of 4pX-1 cells with
the pX1-78-expressing retrovirus was monitored at 24 to 72 h
postinfection by immunofluorescence microscopy using the
Myc antibody (Fig. 6B).
Since amino acids 1 to 50 of pX were reported to mediate
pX oligomerization (31), we determined the effect of pX1-78 on
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FIG. 5. Pulse-chase study of WT pX and pX1-140. 4pX-1, and 4pX1-140
cell lines grown without tetracycline for 24 h to express WT pX and
pX1-140, respectively, were metabolically labeled with [35S]methionine
for 2 h, followed by incubation in [35S]methionine-free medium for
various times (0 h, 30 min, and 1, 2, and 4 h). Cellular extracts were
immunoprecipitated using a pX-specific antibody and analyzed by 14%
SDS-PAGE and autoradiography. A representative assay is shown.

pX-mediated mitogenic pathway activation, employing the
4pX cell lines expressing either WT pX or deletions pX1-140
and pX51-140. These pX deletions activate the mitogenic pathways (Fig. 2), induce endogenous cyclin A expression (Fig.
3A), and mediate apoptosis (Fig. 4). Thus, 4pX-1, 4pX1-140,
and 4pX51-140 cell lines were infected either with the control
retrovirus murine stem cell virus (MSCV) or MSCV-X1-78.
Transient transreporter assays were performed in retrovirusinfected cells, monitoring activation of the JNK (Fig. 6C) and
p38 MAPK (Fig. 6D) pathways as a function of WT pX, pX1-140,
or pX51-140 expression in the respective cell lines. Infection
with the control MSCV retrovirus does not affect pX-dependent activation of either the JNK or p38 MAPK pathway (Fig.
6C and D). Moreover, expression of deletions pX1-140 and
pX51-140 increased pathway activation in comparison to WT
pX, as shown above (Fig. 2B and C). Interestingly, infection
with MSCV-X1-78 retrovirus expressing pX1-78 reduces JNK
and p38 MAPK pathway activation mediated by WT pX and
pX1-140 by at least 50% (Fig. 6C and D). By contrast, pX1-78
expressed in the 4pX51-140 cell line does not affect pX51-140 in
activating the JNK and p38 MAPK pathways (Fig. 6C and D).
To further confirm these observations, we monitored expression of the endogenous cyclin A gene (Fig. 7A). Infection with
the control MSCV retrovirus does not affect pX-dependent
induction of endogenous cyclin A in the 4pX-1, 4pX1-140, and
4pX51-140 cell lines expressing WT pX or the active pX deletions (Fig. 7A). By contrast, infection with MSCV-X1-78 retrovirus expressing pX1-78 (Fig. 7A) suppresses pX-mediated cyclin A induction to basal levels in 4pX-1 and 4pX1-140 cell lines,
without an effect in the 4pX51-140 cell line. Similarly, pX1-78
expression suppresses apoptosis mediated by WT pX and
pX1-140 (Fig. 7B). Although the effect of pX1-78 on apoptosis
mediated by pX1-140 is smaller than its effect on WT pX, it is
reproducible. By contrast, pX1-78 does not rescue apoptosis
mediated by pX51-140 (Fig. 7B). Infection with MSCV-X1-78
further enhances apoptosis in the 4pX51-140 cell line, suggesting that X1-78 acts either as a stress signal acting synergistically
with pX51-140 or that it interacts with cellular factors involved
in apoptosis. We conclude that pX1-78 exerts a dominant-neg-
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ative effect, interfering with pX function only when the Nterminal amino acids 1 to 50 are present.
pX1-78 coimmunoprecipitates with WT pX. To determine the
mechanism by which pX1-78 interferes with WT pX function,
we investigated whether pX1-78 interacts directly with pX.
4pX-1 cells expressing WT pX were infected with the control
MSCV retrovirus or MSCV-X1-78. Cellular extracts were isolated from infected 4pX-1 cells expressing pX and immunoprecipitated either with a Myc antibody recognizing the Myc
epitope fused to pX1-78 (Fig. 8A, lanes 1 and 2) or a pX
antibody (Fig. 8A, lanes 3 and 4). The Myc antibody immunoprecipitates were analyzed by Western blotting using a pX
antibody, identifying a 16.5-kDa band only when 4pX-1 cells
expressing pX were infected with the MSCV-X1-78 retrovirus
(Fig. 8A, lane 1). Likewise, the immunoprecipitates with the
pX antibody, immunoblotted with the Myc antibody, detect a
band comigrating with pX1-78 (lane 5) only when 4pX-1 cells
expressing pX were infected with the MSCV-X1-78 retrovirus
(Fig. 8A, lane 3). Importantly, by Western blot analysis, the pX
antibody does not detect pX1-78 (data not shown). These results conclusively demonstrate that WT pX interacts directly
with pX1-78, indicating that this pX region is the site of direct
protein-protein interactions of X-protein molecules leading to
pX oligomerization.
In Fig. 6B, a time-dependent nuclear translocation of X1-78
is observed. Since our results (Fig. 8A) demonstrate that
pX1-78 interacts with WT pX, to further confirm these observations, we examined by immunofluorescence microscopy the
rate of nuclear translocation of X1-78 as a function of expression of WT pX, X1-140, or X51-140. The localization of pX1-78
was monitored by immunofluorescence microscopy using the
Myc antibody in a time course experiment 8 h to 24 h following
expression of WT pX, X1-140, or X51-140 in the corresponding
cell lines infected with MSCV-X1-78 retrovirus (Fig. 8B). Expression of WT pX and pX1-140 results in the nuclear localization of pX1-78 within 12 h of their expression, whereas in the
absence of WT pX and pX1-140, nuclear pX1-78 is detected by
24 h. Importantly, expression of X51-140 does not enhance the
rate of nuclear localization of X1-78 (Fig. 8B). Taken together
(Fig. 6 to 8), the results conclusively demonstrate that pX1-78
interacts with pX via the N-terminal amino acids 1 to 50.
DISCUSSION
In this study we demonstrate that the pX region spanning
amino acids 50 to 140 is essential for activation of the mitogenic pathways. In contrast to an earlier report (33), we demonstrate that amino acids 116 to 140 of pX are necessary for
mitogenic pathway activation and endogenous gene expression
and for mediating cell growth outcomes, such as apoptosis.
Our analyses have also led to the identification of two regions
located at the N terminus and C terminus of the X protein
which modulate X-protein function. The C-terminal region
spanning aa 141 to 154 determines X-protein stability. The
N-terminal region, amino acids 1 to 78 of pX, is the site of
direct protein-protein interactions between X molecules.
Construction of tetracycline-regulated cell lines expressing
pX deletions. We have earlier demonstrated by systematic deletion analyses of pX that amino acids 51 to 140 are required
for pX-dependent CREB/ATF-mediated transcription (4).
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FIG. 6. (A) pX1-78 expression in PT67-pMSCV-X1-78 cell line.
(Left) Direct fluorescence microscopy of enhanced green fluorescent
protein (EGFP) in the PT67-pMSCV-EGFP cell line. Immunofluorescence microscopy was performed on stably transfected PT67 cells
stained with Myc antibody, recognizing the Myc epitope fused to pX1-78.
(Right) Western blot of thePT67-pMSCV-X1-78 cell line expressing
pX1-78, employing the Myc antibody. The positions of molecular mass
standards (in kilodaltons) are shown in the gel. (B) pX1-78 expression
in MSCV-X1-78 virus-infected 4pX-1 cells. Immunofluorescence microscopy was performed on 4pX-1 cells infected with the indicated
retroviruses using the Myc antibody. (C and D) Transient transreporter
assays in 4pX-1, 4pX1-140, and 4pX51-140 cell lines infected with control
MSCV or MSCV-X1-78 retroviruses. Forty-eight hours after infection,
cells were transfected with pFA-c-Jun and pFR-Luc plasmids (C) or
pFA-Chop10 and pFR-Luc (D). Twelve hours following transfection, WT
pX, pX1-140, and X51-140 were expressed for 24 h by tetracycline removal.
Luciferase activity was normalized per microgram of protein extract. Results are from at least three independent experiments (three identical
experiments). Values for the pX deletion in MSCV-X1-78-infected cells
that were statistically significantly different from the value for MSCVinfected cells are indicated by an asterisk(s).

Herein, employing the same pX deletions, we determined the
pX region required for activation of the mitogenic pathways.
The activity of pX deletions was determined by constructing
tetracycline-regulated cell lines expressing these pX deletions
in the AML12 clone 4 cell line (40). Expression of WT pX in
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an AML12 clone 4 4pX-1 cell line mediates sustained activation of the JNK and p38 MAPK pathways and transient activation of the Ras-Raf-MAPK pathway (42). Furthermore, the
sustained, pX-dependent activation of the JNK and p38
MAPK pathways in 4pX-1 cells mediates pX-dependent induction of endogenous cyclin A transcription (28, 42) and pXdependent sensitization to apoptosis (44). Accordingly, on the
basis of our earlier studies of the 4pX-1 cell line (28, 40, 42,
44), the AML12 clone 4 cell lines expressing the indicated
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FIG. 7. (A) pX-dependent induction (in the absence of Tet/in
the presence of Tet [⫺Tet/⫹Tet]) of endogenous cyclin A in 4pX-1,
4pX1-140, and 4pX51-140 cell lines infected with control MSCV or
MSCV-X1-78 retroviruses for 48 h. Endogenous cyclin A mRNA was
quantified by real-time PCR, employing RNA isolated from the indicated retrovirus-infected 4pX cells expressing WT pX, pX1-140, and
X51-140 for 12 h by tetracycline removal. Quantification was performed
using endogenous glyceraldehyde-3-phosphate dehydrogenase as an
internal control. Results are from at least three independent RNA
preparations using identical PCR triplicate experiments. Values for
the pX deletion in MSCV-X1-78-infected cells that were statistically
significantly different from the value for MSCV-infected cells are indicated by an asterisk(s). (B) Relative pX-dependent (⫺Tet/⫹Tet)
apoptosis in 4pX-1, 4pX1-140, and 4pX51-140 cell lines infected with
control MSCV or MSCV-X1-78 retroviruses, assayed by immunofluorescence microscopy with the active, cleaved caspase 3-specific antibody.
Quantification of immunofluorescence images was by IMAGE J software.
Results are from at least three independent apoptotic assays, quantifying
an average of 5,000 cells per assay. Values for WT pX in MSCVX1-78-infected cells that were statistically significantly different from the
value for MSCV-infected cells are indicated by an asterisk(s).

pX deletions enabled us to determine not only the direct
activation of the mitogenic pathways by transient transreporter assays but also the consequence of their activation, by
measuring the effect of each pX deletion on endogenous
cyclin A gene expression and on cell growth outcomes, such
as apoptosis.
pX51-140 mediates sustained JNK pathway activation, inducing endogenous gene expression and apoptosis. Transient transreporter assays measure the direct activation of a specific mitogenic pathway in vivo. In the 4pX cell lines expressing the
various pX deletions, the ratio (induction) of transreporter
activity, measured in the presence (in the absence of Tet)
versus absence (in the presence of Tet) of each pX deletion,
can be directly compared. The transreporter induction moni-
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toring activation of the Ras-Raf-MAPK, JNK, and p38 MAPK
pathways by pX79-154 and pX1-140, containing a deletion of the
N-terminal amino acid residues 1 to 78 and C-terminal amino
acid residues 141 to 154, respectively, displays a reproducible
increase relative to WT pX. Importantly, pX51-140 in which
both these N- and C-terminal regions have been deleted mediated a statistically significant increase (P ⬍ 0.005) in transreporter induction for the Ras-Raf-MAPK, JNK, and p38
MAPK (P ⬍ 0.05) pathways in comparison to WT pX. A larger
C-terminal deletion of amino acids 116 to 154 in pX1-115 abolished activation of all the mitogenic pathways, demonstrating
that amino acids 116 to 140 are necessary for pX-dependent
mitogenic pathway activation. We conclude that the pX region
containing amino acid residues 51 to 140 is essential for activation of all the mitogenic pathways. In support of this conclusion, we also demonstrate that the MEK-1-, JNK- and p38
MAPK-specific inhibitors inhibit activation of the respective
mitogenic pathway by pX51-140. Furthermore, the enhanced
activity of pX51-140 in comparison to WT pX suggests that these
N-terminal and C-terminal regions modulate pX function.
In the 4pX-1 cell line, expression of WT pX induces transcription of the endogenous cyclin A gene via the pX-dependent, sustained activation of the JNK and p38 MAPK pathways
(28, 42). pX deletions pX51-154, pX79-154, pX51-115, pX1-140 and
pX51-140 activate all the mitogenic pathways tested by the transient transreporter assay system. However, only 4pX cell lines
expressing pX1-140 and pX51-140 displayed pX-dependent induction of endogenous cyclin A. In vitro JNK assays demonstrated that only pX1-140 and pX51-140 mediate sustained JNK
pathway activation, a requirement for endogenous cyclin A
expression (11). Furthermore, similar to WT pX (44), only
pX1-140 and pX51-140 sensitize the respective 4pX cell lines to
apoptosis. pX-mediated apoptosis, as we have shown earlier
(44), requires sustained activation of the p38 MAPK and JNK
pathways. Importantly, neither pX1-115 nor pX51-115 induces
endogenous cyclin A transcription or apoptosis, both assays
relying on the potential of the pX deletions to mediate sustained activation of the mitogenic cascades. Thus, these results
underscore the significance of the duration of mitogenic pathway activation in altering cell growth outcomes, e.g., progression in the cell cycle, apoptosis, or transformation.
Moreover, our results identifying pX51-140 as essential for
activation of the mitogenic pathways agree with the activity of
the linker scanning mutants of pX, spanning amino acids 53 to
139 and displaying loss of apoptosis (37). However, our results
are not in agreement with the conclusions reported by Nijhara
et al. (33), namely, that the pX region spanning amino acids 58
to 119 is sufficient for the activation of mitogenic pathways.
Similar to our transient transreporter result with pX51-115 (Fig.
2), it is likely that residual mitogenic activity in pX58-119, the
absence of the modulatory N-terminal region, or overexpression of pX58-119 accounts for the observed mitogenic pathway
activation (33). In our cellular model system (40, 42, 44), the
expression levels of pX and all the pX deletions are very low
(Table 1), resembling the pX expression level observed during
natural HBV infection (21). Moreover, our conclusion that
pX51-140 is required for mitogenic pathway activation is derived
from both transient transreporter assays and physiologically
relevant assays measuring pX-dependent endogenous gene expression and apoptosis.
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FIG. 8. (A) Cellular extracts were isolated from 4pX-1 cells infected for 48 h with MSCV-X1-78 or control MSCV retroviruses and
induced to express WT pX for 24 h by tetracycline removal. Whole-cell
extract (2 mg) was immunoprecipitated with Myc antibody, recognizing the Myc-pX1-78 fusion protein (lanes 1 and 2) or with pX antibody
(lanes 3 and 4). Immunoprecipitates (IP) were analyzed by 14% SDSPAGE and immunoblotted with pX antibody (Ab) (lanes 1 and 2) or
Myc antibody (lanes 3 and 4). Lane 5, immunoblot of whole-cell
extracts isolated from PT67-X1-78 cell line. WB, Western blot. (B) Immunofluorescence microscopy of 4pX-1, 4pX1-140, and 4pX51-140 cell
lines infected for 48 h with MSCV-X1-78 retrovirus followed by expression of pX deletions for the indicated time course, employing the Myc
antibody (green). Hoechst (blue) stains DNA.

The comparative analyses of pX51-154 and pX51-140 suggested
that the C-terminal region containing amino acids 141 to 154
modulates pX function. Pulse-chase studies shown herein demonstrate the increased half-life of pX1-140 relative to that of
WT pX, supporting the hypothesis that the C-terminal 14
amino acids determine pX stability. Interestingly, naturally occurring pX variants found integrated in genomic DNA from
liver tumors of patients with HCC contained C-terminal deletions generally lacking amino acids 134 to 154 (36, 43, 46).
Thus, the increased protein stability of these pX variants may
be a contributing factor in HCC development.
pX1-78 has a dominant-negative effect of WT X-protein function. The enhanced mitogenic activity of pX51-140 demonstrated herein, together with earlier reports that the N terminus of pX negatively regulates pX-dependent transactivation
(31), prompted us to examine whether pX1-78 interferes with

WT X-protein function. pX1-78 expressed via the MSCVpX1-78 retrovirus inhibits mitogenic pathway activation and
endogenous cyclin A expression and suppresses apoptosis in
4pX cell lines expressing WT pX and pX1-140 without an effect
on pX51-140 lacking the 50 N-terminal amino acid residues.
Coimmunoprecipitations of WT pX with pX1-78 established
that pX1-78 interferes with WT pX function by interacting
directly with WT pX. The absence of a dominant-negative
effect of pX1-78 on the mitogenic activities of pX51-140 supports
the hypothesis that the N-terminal amino acid residues 1 to 50
constitute the site of direct X-protein-protein interactions.
This is the first conclusive evidence of direct protein-protein
interactions involving the N terminus of pX. Whether these
protein-protein interactions lead to pX dimerization or to
formation of more complex oligomers remains to be determined.
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